Advertisement

General Treatment Strategies

Chapter
  • 571 Downloads

Key Chapter Points

Initial treatment for patients with non-traumatic, primary headache includes rehydration and aggressive treatment of nausea. Patients with severe headache pain may need treatment with headache-specific therapies (i.e., triptans or dihydroergotamine) or non-opioid analgesics (i.e., ketorolac). Additional options include intravenous magnesium, intravenous valproate, trigger point injections, and occipital nerve blocks. Steroids offer minimal benefit, although intravenous dexamethasone may help patients with disabling primary headache lasting over 3 days. Opioids should be reserved for rescue therapy in the ED and not routinely used provided as take-home medication.

Keywords

Anti-emetic Hydration Injection Occipital nerve block Trigger point 

References

  1. 1.
    Wöber C, Wöber-Bingöl C. Triggers of migraine and tension-type headache. Handb Clin Neurol. 2010;97:161–72.PubMedCrossRefGoogle Scholar
  2. 2.
    Blau JN. Water deprivation: a new migraine precipitant. Headache. 2005;45:757–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Martins IP, Gouveia RG. More on water and migraine. Cephalalgia. 2007;27:372–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Spigt MG, Kuijper EC, Schayck CP, et al. Increasing daily water intake for prophylactic treatment of headache: a pilot trial. Eur J Neurol. 2005;12:715–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Hurtado TR, Vinson DR, Vandenberg JT. ED treatment of migraine headache: factors influencing pharmacotherapeutic choices. Headache. 2007;47:1134–43.PubMedCrossRefGoogle Scholar
  6. 6.
    Kelly AM, Walcynski T, Gunn B. The relative efficacy of phenothiazines for the treatment of acute migraine: a meta-analysis. Headache. 2009;49:1324–32.PubMedCrossRefGoogle Scholar
  7. 7.
    Friedman BW, Esses D, Solorzano C, et al. A randomized controlled trial of prochlorperazine versus metoclopramide for treatment of acute migraine. Ann Emerg Med. 2008;52:399–406.PubMedCrossRefGoogle Scholar
  8. 8.
    Miner JR, Fish SJ, Smith SW, Biros MH. Droperidol vs. prochlorperazine for benign headaches in the emergency department. Acad Emerg Med. 2001;8:873–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Richman PB, Allegra J, Eskin B, et al. A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine. Am J Emerg Med. 2002;20:39–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Dusitanond P, Young WB. Neuroleptics and migraine. Cent Nerv Syst Agents Med Chem. 2009;9:63–70.PubMedCrossRefGoogle Scholar
  11. 11.
    Ayad RF, Assar MD, Simpson L, Garner JB, Schussler JM. Causes and management of drug-induced QT syndrome. Proc (Baylor Univ Med Cent). 2010;23:250–5.Google Scholar
  12. 12.
    Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf. 2010;5:105–11.PubMedCrossRefGoogle Scholar
  13. 13.
    Dusitanond P, Young WB. Neuroleptics and migraine. Cent Nerv Syst Agents Med Chem. 2009;9:63–70.PubMedCrossRefGoogle Scholar
  14. 14.
    Griffith JD, Mycyck MB, Kyriacou DN. Metoclopramide versus hydrocodone for the emergency department treatment of migraine headache. J Pain. 2008;9:88–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Cicek M, Karcioglu O, Pariak I, et al. Prospective, randomized, double-blind, controlled comparison of metoclopramide and pethidine in the emergency treatment of acute primary vascular and tension-type headache episodes. Emerg Med J. 2004;21:323–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Friedman BW, Corbo J, Lipton RB. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology. 2005;64:463–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Friedman BW, Hockberg M, Esses D, et al. A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraine. Headache. 2006;46:934–41.PubMedCrossRefGoogle Scholar
  18. 18.
    Kostic MA, Gutierrez FJ, Rieg TS, Moore TS, Gendrom RT. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med. 2010;56:1–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Dillard JN, Knapp S. Complementary and alternative pain therapy in the emergency department. Emerg Med Clin N Am. 2005;23:529–49.CrossRefGoogle Scholar
  20. 20.
    Gupta MX, Silberstein SD, Young WB, et al. Less is not more: underutilization of headache medications in a university hospital emergency department. Headache. 2007;47:1125–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Vinson DR, Hurtado TR, Vandenberg JT, Banwart L. Variations among emergency departments in the treatment of benign headache. Ann Emerg Med. 2003;41:90–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Trainor A, Miner J. Pain treatment and relief among patients with primary headache subtypes in the ED. Am J Emerg. 2008;26:1029–34.CrossRefGoogle Scholar
  23. 23.
    Friedman D, Feldon S, Holloway R, Fisher S. Utilization, diagnosis, treatment and cost of migraine treatment in the emergency department. Headache. 2009;49:1163–73.PubMedCrossRefGoogle Scholar
  24. 24.
    Evers A, Áfra J, Frese A, et al. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur J Neurol. 2009;16:968–81.PubMedCrossRefGoogle Scholar
  25. 25.
    Miner JR, Smith SW, Moore J, Biros M. Sumatriptan for the treatment of undifferentiated primary headaches in the ED. Am J Emerg Med. 2007;25:60–4.PubMedCrossRefGoogle Scholar
  26. 26.
    Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia. 1996;16:554–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Martin VT, Goldstein JA. Evaluating the safety and tolerability profile of acute treatments for migraine. Am J Med. 2005;118(Suppl):36S–44S.PubMedGoogle Scholar
  28. 28.
    Wendt J, Cady R, Singer R, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin Ther. 2006;28:517–26.PubMedCrossRefGoogle Scholar
  29. 29.
    Carleston SG, Shesser RF, Pietrzak MP, et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med. 1998;32:129–38.CrossRefGoogle Scholar
  30. 30.
    Seim MB, March JA, Dunn KA. Intravenous ketorolac vs intravenous prochlorperazine for the treatment of migraine headaches. Acad Emerg Med. 1998;5:573–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med. 2004;43:256–62.PubMedCrossRefGoogle Scholar
  32. 32.
    Meredith JT, Wait S, Brewer KL. A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med. 2003;21:173–5.PubMedCrossRefGoogle Scholar
  33. 33.
    Alemdar M, Pekdemir M, Selekler HM. Single-dose intravenous tramadol for acute migraine pain in adults: a single-blind, prospective, randomized, placebo-controlled clinical trail. Clin Ther. 2007;29:1441–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Engindeniz Z, Demircan C, Karli N, et al. Intramuscular tramadol vs. diclofenac sodium for the treatment of acute migraine attacks in emergency department: a prospective, randomized, double-blind study. J Headache Pain. 2005;6:143–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Tanen DA, Miller S, French T, Riffenburgh RH. Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. Ann Emerg Med. 2003;41:847–53.PubMedCrossRefGoogle Scholar
  36. 36.
    Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headaches. Headache. 2001;41:976–80.PubMedCrossRefGoogle Scholar
  37. 37.
    Deutsch SI, Burket JA, Rosse RB. Valproate-induced hyperammonemic encephalopathy and normal liver functions: possible synergism with topiramate. Clin Neuropharmacol. 2009;32:350–2.PubMedCrossRefGoogle Scholar
  38. 38.
    Vivekanandan S, Nayak SD. Valproate-induced hyperammonemic encephalopathy enhanced by topiramate and phenobarbitone: a case report and an update. Ann Indian Acad Neurol. 2010;13:145–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002;22:345–53.PubMedCrossRefGoogle Scholar
  40. 40.
    Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia. 2005;25:199–204.PubMedCrossRefGoogle Scholar
  41. 41.
    Friedman BW, Greenwald P, Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007;69:2038–44.PubMedCrossRefGoogle Scholar
  42. 42.
    Kelly AM, Kerr D, Clooney M. Impact of oral dexamethasone versus placebo after ED treatment of migraine with phenothiazines on the rate of recurrent headache: a randomized controlled trial. Emerg Med J. 2008;25:26–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Friedman BW, Greenwald P. Bania, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology. 2007;69:2038–44.PubMedCrossRefGoogle Scholar
  44. 44.
    Rowe BH, Colman I, Edmonds ML, et al. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache. Headache. 2008;28:333–40.CrossRefGoogle Scholar
  45. 45.
    Donaldson D, Sundermann R, Jackson R, Bastani A. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blind, placebo-controlled randomized clinical trial. Am J Emerg Med. 2008;26:124–30.PubMedCrossRefGoogle Scholar
  46. 46.
    Kapicioğlu S, Gökce E, Kapicioğlu Z, Ovali E. Treatment of migraine attacks with a long-acting somatostatin analogue (octreotide, SMS 2010–995). Cephalalgia. 1997;17:27–30.PubMedCrossRefGoogle Scholar
  47. 47.
    Miller MA, Levsky ME, Enslow W, Rosin A. Randomized evaluation of octretide vs prochlorperazine for ED treatment of migraine headache. Am J Emerg Med. 2009;27:160–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Colman I, Rothney A, Wright SC, Zilkalns B, Rowe BH. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology. 2004;62:1695–700.PubMedGoogle Scholar
  49. 49.
    Schuckman H, Hazelett S, Powell C, Steer S. A validation of self-reported substance use with biochemical testing among patients presenting to the emergency department seeking treatment for backache, headache, and toothache. Subst Use Misuse. 2008;43:589–95.PubMedCrossRefGoogle Scholar
  50. 50.
    Braden JB, Russo J, Fan MY, et al. Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med. 2010;170:1425–32.PubMedCrossRefGoogle Scholar
  51. 51.
    Tornabene SV, Deutsch R, Davis DP, Chan TC, Vilke GM. Evaluating the use and timing of opioids for the treatment of migraine headaches in the emergency department. J Emerg Med. 2009;36:333–7.PubMedCrossRefGoogle Scholar
  52. 52.
    Cohen AS, Burns B, Goadsby PJ. High-flow oxygen for treatment of cluster headache: a randomized trial. JAMA. 2009;302:2451–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Law S, Derry S, Moore RA. Triptans for acute cluster headache. Cochrane Database Syst Rev. 2010;4:CD008042.PubMedGoogle Scholar
  54. 54.
    May A, Leone M, Afra J, et al. EFNS Task Force. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol. 2006;13:1066–77.PubMedCrossRefGoogle Scholar
  55. 55.
    Halker R, Vargas B, Dodick DW. Cluster headache: diagnosis and treatment. Semin Neurol. 2010;30:175–85.PubMedCrossRefGoogle Scholar
  56. 56.
    Blumfeld A, Ashkenazi A, Grosberg B, et al. Patterns of use of peripheral nerve blocks and trigger point injections among headache practitioners in the USA: results of the American Headache Society Interventional Procedure Survey (AHS-IPS). Headache. 2010;50:937–42.CrossRefGoogle Scholar
  57. 57.
    Simons DG, Travell JG, Simons LS. Myofascial pain and dysfunction: the trigger point manual, vol 1. 2nd ed. Baltimore: Lippincott Williams & Wilkins; 1999.Google Scholar
  58. 58.
    Edwards J, Knowles N. Superficial dry needling and active stretching in the treatment of myofascial pain – a randomized controlled trial. Acupunct Med. 2003;21:80–6.PubMedCrossRefGoogle Scholar
  59. 59.
    Hsieh YL, Kao MJ, Kuan TS, et al. Dry needling to a key myofascial trigger point may reduce the irritability of satellite MTrPs. Am J Phys Med Rehabil. 2007;86(5):397–403.PubMedCrossRefGoogle Scholar
  60. 60.
    Cummings TM, White AR. Needling therapies in the management of myofascial trigger point pain: a systematic review. Arch Phys Med Rehabil. 2001;82:986–92.PubMedCrossRefGoogle Scholar
  61. 61.
    Weibelt S, Andress-Rothrock D, King W, Rothrock J. Suboccipital nerve blocks for suppression of chronic migraine: safety, efficacy, and predictors of outcome. Headache. 2010;50:1041–4.PubMedCrossRefGoogle Scholar
  62. 62.
    Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache symptoms – prolonged effects from a single injection. Pain. 2006;122:126–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Loukas M, El-Sedfy A, Tubbs RS, et al. Identification of greater occipital nerve landmarks for the treatment of occipital neuralgia. Folia Morphol. 2006;65:337–42.Google Scholar
  64. 64.
    Mellick LB, Mcllrath ST, Gellick GA. Treatment of headaches in the ED with lower cervical intramuscular bupivacaine injections: a 1-year retrospective review of 417 patients. Headache. 2006;46:1441–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Friedman BW, Bijur PE, Lipton RB. Standardizing emergency department-based migraine research: an analysis of commonly used clinical trial outcome measures. Acad Emerg Med. 2010;17:72–9.PubMedCrossRefGoogle Scholar
  66. 66.
    Friedman BW, Solorzano C, Esses D, et al. Treating headache recurrence after emergency department discharge: a randomized controlled trial of naproxen versus sumatriptan. Ann Emerg Med. 2010;56(1):7–17.PubMedCrossRefGoogle Scholar
  67. 67.
    Rowe BH, Colman I, Edmonds ML, et al. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headaches. Headache. 2008;48:3330340.CrossRefGoogle Scholar
  68. 68.
    Fiesseler FW, Shih R, Szucs P, et al. Steroids for migraine headaches: a randomized double-blind, two-armed, placebo-controlled trial. J Emerg Med. 2011;40(4):463–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Singh A, Alter HJ, Zaia B. Does the addition of dexamethasone to standard therapy for acute migraine decrease the incidence of recurrent headache for patients treated in the emergency department? A meta-analysis and systematic review of the literature. Acad Emerg Med. 2008;15:1223–33.PubMedCrossRefGoogle Scholar
  70. 70.
    Aurora S, Kori S, Barrodale P, Nelsen A, McDonald S. Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache. 2007;47:1443–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of AnesthesiologyUniversity of PittsburghPittsburghUSA
  2. 2.Dean Health SystemsMadisonUSA

Personalised recommendations